Changes in characteristics of drug overdose death trends during the COVID-19 pandemic.


Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
12 2021
Historique:
received: 03 03 2021
revised: 13 07 2021
accepted: 14 07 2021
pubmed: 30 7 2021
medline: 18 12 2021
entrez: 29 7 2021
Statut: ppublish

Résumé

Reports analyzing drug overdose (OD) mortality data during the COVID-19 pandemic are limited. Outcomes across states are heterogenous, necessitating assessments of associations between COVID-19 and OD deaths on a state-by-state level. This report aims to analyze trends in OD deaths in Massachusetts during COVID-19. Analyzing 3,924 death records, we characterize opioid-, cocaine-, and amphetamine-involved OD mortality and substance co-presence trends from March 24-November 8 in 2020 as compared to 2018 and 2019. OD deaths involving amphetamines increased by 85% from 2019 to 2020 (61 vs. 113; P<0.001) but were steady from 2018 to 2019. Heroin's presence continued to decrease (341 in 2018, 247 in 2019, 157 in 2020; P<0.001); however, fentanyl was present in more than 85% of all OD deaths across all periods. Among OD deaths, alcohol involvement consistently increased, present in 250 deaths in 2018, 299 in 2019 (P=0.02), and 350 in 2020 (P=0.04). In 2019, 78% of OD decedents were White and 7% were Black, versus 73% and 10% in 2020 (P=0.02). Increased deaths involving stimulants, alcohol, and fentanyl reflect concerning trends in the era of COVID-19. Rising OD death rates among Black residents underscore that interventions focused on racial equity are necessary.

Sections du résumé

BACKGROUND
Reports analyzing drug overdose (OD) mortality data during the COVID-19 pandemic are limited. Outcomes across states are heterogenous, necessitating assessments of associations between COVID-19 and OD deaths on a state-by-state level. This report aims to analyze trends in OD deaths in Massachusetts during COVID-19.
METHODS
Analyzing 3,924 death records, we characterize opioid-, cocaine-, and amphetamine-involved OD mortality and substance co-presence trends from March 24-November 8 in 2020 as compared to 2018 and 2019.
RESULTS
OD deaths involving amphetamines increased by 85% from 2019 to 2020 (61 vs. 113; P<0.001) but were steady from 2018 to 2019. Heroin's presence continued to decrease (341 in 2018, 247 in 2019, 157 in 2020; P<0.001); however, fentanyl was present in more than 85% of all OD deaths across all periods. Among OD deaths, alcohol involvement consistently increased, present in 250 deaths in 2018, 299 in 2019 (P=0.02), and 350 in 2020 (P=0.04). In 2019, 78% of OD decedents were White and 7% were Black, versus 73% and 10% in 2020 (P=0.02).
CONCLUSION
Increased deaths involving stimulants, alcohol, and fentanyl reflect concerning trends in the era of COVID-19. Rising OD death rates among Black residents underscore that interventions focused on racial equity are necessary.

Identifiants

pubmed: 34325184
pii: S0955-3959(21)00297-8
doi: 10.1016/j.drugpo.2021.103392
pmc: PMC9759694
pii:
doi:

Substances chimiques

Analgesics, Opioid 0
Fentanyl UF599785JZ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103392

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of Interest The authors declare no competing interests.

Références

Am J Public Health. 2021 Jul;111(7):1284-1291
pubmed: 33856885
MMWR Morb Mortal Wkly Rep. 2020 Sep 04;69(35):1189-1197
pubmed: 32881854
J Urban Health. 2020 Dec;97(6):808-813
pubmed: 32989667
JAMA Netw Open. 2020 Sep 1;3(9):e2022942
pubmed: 32990735
J Law Med Ethics. 2018 Jun;46(2):404-421
pubmed: 30146996
Addiction. 2020 May;115(5):946-958
pubmed: 31912625
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1049-1057
pubmed: 32790653
Nat Med. 2020 Jun;26(6):819-820
pubmed: 32555514
Science. 2018 Sep 21;361(6408):
pubmed: 30237320
J Urban Health. 2020 Dec;97(6):802-807
pubmed: 33005988

Auteurs

Catherine DiGennaro (C)

Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, United States.

Gian-Gabriel P Garcia (GP)

Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, United States.

Erin J Stringfellow (EJ)

Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, United States.

Sarah Wakeman (S)

Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, United States.

Mohammad S Jalali (MS)

Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, United States. Electronic address: msjalali@mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH